Macimorelin Side Effects: Safety Signals and Warnings
Macimorelin safety concerns are compound-specific. The main listed side effects are Dysgeusia (taste disturbance), Dizziness, and Headache. The main warning signals are Approved only as a single-dose diagnostic agent - not for chronic GH stimulation, False positive results possible in patients on strong CYP3A4 inducers, and QTc prolongation observed at supratherapeutic doses - caution in patients with cardiac risk factors.
Direct Answer
Macimorelin (Macrilen) is FDA-approved as the first oral diagnostic test for adult GH deficiency, replacing the insulin tolerance test in many clinical settings. Its role is diagnostic, not therapeutic. For researchers studying the GH/IGF-1 axis and needing a validated, reproducible stimulation test, macimorelin is the current standard of care with actual FDA approval behind it.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Growth Hormone
- Best for
- Adult GH deficiency diagnosis, GH stimulation testing, GH axis research
Reported Side Effects
- Dysgeusia (taste disturbance)
- Dizziness
- Headache
- Nausea
- Fatigue
- Hunger
Warnings
- Approved only as a single-dose diagnostic agent - not for chronic GH stimulation
- False positive results possible in patients on strong CYP3A4 inducers
- QTc prolongation observed at supratherapeutic doses - caution in patients with cardiac risk factors
- Fasting for at least 8 hours required before the test
Known or Plausible Interactions
- CYP3A4 inducers (may reduce macimorelin levels, causing false positive results)
- CYP3A4 inhibitors (may increase levels and duration of effect)
- Drugs that affect GH secretion including glucocorticoids, GH itself, and somatostatin analogs (may cause false results)
- QT-prolonging medications (additive effect on QTc interval)
Regulatory Context
FDA approved (2017, Macrilen). Prescription required. Not a controlled substance. Indicated only for diagnostic use.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | GH Deficiency Diagnosis (Level A) and Acute GH Release (Level A) |
| Primary citation count | 2 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Macimorelin Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/macimorelin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.